Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Aug 2023
Price :
$35
*
At a glance
- Drugs Apomorphine (Primary) ; Moxifloxacin
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms CTH-201
- Sponsors Cynapsus Therapeutics; Sunovion Pharmaceuticals
- 16 Sep 2020 Results presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 21 Dec 2017 Status changed from active, no longer recruiting to completed.
- 08 Nov 2017 Status changed from recruiting to active, no longer recruiting.